These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 17196206

  • 1. Dyslipidemia shifts the tissue factor/tissue factor pathway inhibitor balance toward increased thrombogenicity in atherosclerotic plaques: evidence for a corrective effect of statins.
    Zawadzki C, Susen S, Richard F, Haulon S, Corseaux D, Jeanpierre E, Vincentelli A, Lucas C, Torpier G, Martin A, Van Belle E, Staels B, Jude B.
    Atherosclerosis; 2007 Dec; 195(2):e117-25. PubMed ID: 17196206
    [Abstract] [Full Text] [Related]

  • 2. Circulating monocytes mirror the imbalance in TF and TFPI expression in carotid atherosclerotic plaques with lipid-rich and calcified morphology.
    Basavaraj MG, Sovershaev MA, Egorina EM, Gruber FX, Bogdanov VY, Fallon JT, Østerud B, Mathiesen EB, Hansen JB.
    Thromb Res; 2012 Apr; 129(4):e134-41. PubMed ID: 22178066
    [Abstract] [Full Text] [Related]

  • 3. Tissue factor, tissue factor pathway inhibitor and vascular endothelial growth factor-A in carotid atherosclerotic plaques.
    Migdalski A, Kotschy M, Jawien A.
    Eur J Vasc Endovasc Surg; 2005 Jul; 30(1):41-7. PubMed ID: 15933981
    [Abstract] [Full Text] [Related]

  • 4. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ.
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [Abstract] [Full Text] [Related]

  • 5. Atorvastatin and thrombogenicity of the carotid atherosclerotic plaque: the ATROCAP study.
    Cortellaro M, Cofrancesco E, Arbustini E, Rossi F, Negri A, Tremoli E, Gabrielli L, Camera M.
    Thromb Haemost; 2002 Jul; 88(1):41-7. PubMed ID: 12152675
    [Abstract] [Full Text] [Related]

  • 6. Co-localization of tissue factor and tissue factor pathway inhibitor in coronary atherosclerosis.
    Kaikita K, Takeya M, Ogawa H, Suefuji H, Yasue H, Takahashi K.
    J Pathol; 1999 Jun; 188(2):180-8. PubMed ID: 10398162
    [Abstract] [Full Text] [Related]

  • 7. Presence of tissue factor pathway inhibitor in human atherosclerotic plaques is associated with reduced tissue factor activity.
    Caplice NM, Mueske CS, Kleppe LS, Simari RD.
    Circulation; 1998 Sep 15; 98(11):1051-7. PubMed ID: 9736590
    [Abstract] [Full Text] [Related]

  • 8. Tissue factor pathway inhibitor expression in atherosclerosis.
    Drew AF, Davenport P, Apostolopoulos J, Tipping PG.
    Lab Invest; 1997 Oct 15; 77(4):291-8. PubMed ID: 9354763
    [Abstract] [Full Text] [Related]

  • 9. Tissue factor, tissue pathway factor inhibitor and risk factors of atherosclerosis in patients with chronic limbs ischemia: preliminary study.
    Gosk-Bierska I, Wysokin Ski W, Karnicki K, Adamiec R.
    Int Angiol; 2008 Aug 15; 27(4):296-301. PubMed ID: 18677291
    [Abstract] [Full Text] [Related]

  • 10. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions.
    Badimon JJ, Lettino M, Toschi V, Fuster V, Berrozpe M, Chesebro JH, Badimon L.
    Circulation; 1999 Apr 13; 99(14):1780-7. PubMed ID: 10199872
    [Abstract] [Full Text] [Related]

  • 11. Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischaemic heart disease patients.
    Falciani M, Gori AM, Fedi S, Chiarugi L, Simonetti I, Dabizzi RP, Prisco D, Pepe G, Abbate R, Gensini GF, Neri Serneri GG.
    Thromb Haemost; 1998 Mar 13; 79(3):495-9. PubMed ID: 9531029
    [Abstract] [Full Text] [Related]

  • 12. Tissue factor and its inhibitor in human non-crescentic glomerulonephritis--immunostaining vs plasma and urinary levels.
    Naumnik B, Borawski J, Chyczewski L, Pawlak K, Mysliwiec M.
    Nephrol Dial Transplant; 2006 Dec 13; 21(12):3450-7. PubMed ID: 16982632
    [Abstract] [Full Text] [Related]

  • 13. The extrinsic coagulation cascade and tissue factor pathway inhibitor in macrophages: a potential therapeutic opportunity for atherosclerotic thrombosis.
    Jiang P, Xue D, Zhang Y, Ye L, Liu Y, Makale M, Kesari S, Edgington TS, Liu C.
    Thromb Res; 2014 Apr 13; 133(4):657-66. PubMed ID: 24485401
    [Abstract] [Full Text] [Related]

  • 14. Blood-borne tissue factor activity predicts major cerebrovascular events in patients undergoing carotid endarterectomy: results from a 1-year follow-up study.
    Krupinski J, Turu MM, Font MA, Catena E, Slevin M, Morchon S, Rubio F, Badimon L, Martínez-González J.
    Cerebrovasc Dis; 2008 Apr 13; 25(1-2):32-9. PubMed ID: 18033956
    [Abstract] [Full Text] [Related]

  • 15. Low thrombogenicity of calcified atherosclerotic plaques is associated with bone morphogenetic protein-2-dependent inhibition of tissue factor expression.
    Egorina EM, Sovershaev MA, Bogdanov VY, Sovershaev TA, Fallon JT, Seredkina N, Østerud B, Hansen JB.
    Blood Coagul Fibrinolysis; 2011 Dec 13; 22(8):642-50. PubMed ID: 21897206
    [Abstract] [Full Text] [Related]

  • 16. Expression, localization, and activity of tissue factor pathway inhibitor in normal and atherosclerotic human vessels.
    Crawley J, Lupu F, Westmuckett AD, Severs NJ, Kakkar VV, Lupu C.
    Arterioscler Thromb Vasc Biol; 2000 May 13; 20(5):1362-73. PubMed ID: 10807755
    [Abstract] [Full Text] [Related]

  • 17. Bone morphogenetic protein -7 increases thrombogenicity of lipid-rich atherosclerotic plaques via activation of tissue factor.
    Sovershaev MA, Egorina EM, Bogdanov VY, Seredkina N, Fallon JT, Valkov AY, Østerud B, Hansen JB.
    Thromb Res; 2010 Oct 13; 126(4):306-10. PubMed ID: 20656331
    [Abstract] [Full Text] [Related]

  • 18. Effects of peroxisome proliferator-activated receptor ligands in modulating tissue factor and tissue factor pathway inhibitor in acutely symptomatic carotid atheromas.
    Golledge J, Mangan S, Clancy P.
    Stroke; 2007 May 13; 38(5):1501-8. PubMed ID: 17363721
    [Abstract] [Full Text] [Related]

  • 19. Caspase-3 and tissue factor expression in lipid-rich plaque macrophages: evidence for apoptosis as link between inflammation and atherothrombosis.
    Hutter R, Valdiviezo C, Sauter BV, Savontaus M, Chereshnev I, Carrick FE, Bauriedel G, Lüderitz B, Fallon JT, Fuster V, Badimon JJ.
    Circulation; 2004 Apr 27; 109(16):2001-8. PubMed ID: 15078795
    [Abstract] [Full Text] [Related]

  • 20. Impaired control of the tissue factor pathway of blood coagulation in systemic lupus erythematosus.
    Adams MJ, Palatinus AA, Harvey AM, Khalafallah AA.
    Lupus; 2011 Dec 27; 20(14):1474-83. PubMed ID: 21993387
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.